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Characterization of Anaphylaxis After Ecallantide
Treatment of Hereditary Angioedema Attacks
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Chevy Chase, Md; San Diego, Calif; Cincinnati, Ohio; Dallas, Tex; and Boston and Burlington, MassWhat is already known about this topic? Hypersensitivity reactions have been described in patients who received
ecallantide treatment, with approximately 3% to 4% of patients who experience reactions consistent with anaphylaxis.
What does this article add to our knowledge? This article is a comprehensive retrospective review of documented
cases of hypersensitivity reactions observed in the ecallantide clinical development program that meet the criteria of
anaphylaxis. This is important information for allergists to ensure appropriate observation, preparation, and safety pre-
cautions for the rare occurrence of anaphylaxis when administering ecallantide.
How does this study impact current management guidelines? These data highlight the importance of ecallantide
administration by a health care provider knowledgeable and prepared to treat anaphylaxis.BACKGROUND: Ecallantide is a human plasma kallikrein
inhibitor indicated for treatment of acute attacks of hereditary
angioedema for patients 12 years of age and older. Ecallantide is
produced in Pichia pastoris yeast cells by recombinant DNA
technology. Use of ecallantide has been associated with a risk of
hypersensitivity reactions, including anaphylaxis.
OBJECTIVE: The objective of this detailed retrospective data
review was to characterize anaphylaxis cases within the
ecallantide clinical trials database.
METHODS: Potential cases of hypersensitivity reactions in the
ecallantide clinical development program were identiﬁed by
examining reported adverse events. The National Institute of
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206those events that were consistent with anaphylaxis; these cases
were then reviewed in detail. Results from investigational
antibody testing also were examined.
RESULTS: Among patients who received subcutaneous
ecallantide (n[ 230 patients; 1045 doses of 30 mg ecallantide),
8 patients (3.5%) had reactions that met the National Institute
of Allergy and Infectious Disease criteria for anaphylaxis; none
occurred on ﬁrst exposure to the drug. All 8 reactions had
symptom onset within 1 hour of exposure and cutaneous
manifestations commonly observed in type I hypersensitivity
reactions. All the reactions responded to standard management
of type I hypersensitivity reactions and resolved without fatal
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CRAIG ETAL 207Abbreviations used
e- Negative
þ- PositiveAnti-ecal IgE- anti-ecallantide IgE antibody
AntieP pastoris IgE- antieP pastoris IgE antibodybp- Blood pressure
D5W- 5% dextrose in water
ECL- ElectrochemiluminescentEDEMA- Evaluation of DX-88s Effects in Mitigating
AngioedemaHAE- Hereditary angioedema
HRP- Horseradish peroxidaseHSNC- Human serum negative control
HSR- Hypersensitivity reactionIgE-anti-ecal- Anti-ecallantide IgE antibody
IM- intramuscular
IV- IntravenousLLOQ- Lower limit of quantitation
ND- Not determinedNIAID- National Institute of Allergy and Infectious
DiseaseOD- Optical density
PEF- Peak expiratory ﬂow
PO- oral
sat- Saturation
SC- SubcutaneousTMB- 3,3’,5,5’-Tetramethylbenzidinenot consistently positive in patients who experienced
apparent type I hypersensitivity reactions.
CONCLUSION: Anaphylaxis episodes after subcutaneous
ecallantide exposure have clinical features suggestive of type I
hypersensitivity reactions. However, anti-ecallantide or antieP
pastoris IgE antibody status was not found to be reliably associated
with anaphylaxis.  2014 The Authors. Published by Elsevier
Inc. on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/)
(J Allergy Clin Immunol Pract 2015;3:206-12)
Key words: Hypersensitivity; Anaphylaxis; Allergy; Hereditary
angioedema; Ecallantide; HAE
Hereditary angioedema (HAE) is a rare disease characterized
by prolonged, unpredictable attacks of nonpitting, nonpruritic
edema of the subcutaneous (SC) tissue and mucosa. It is caused
by a deﬁciency in functional C1-inhibitor, a serine-protease
inhibitor of the plasma kallikrein-kinin, coagulation and com-
plement systems. Swelling occurs most commonly in the face,
extremities, gastrointestinal tract, and genitalia.1 Swelling of the
laryngeal area is of serious medical concern because it can result
in airway compromise and asphyxiation.2,3 During an HAE
attack, unregulated plasma kallikrein activity results in excessive
production of bradykinin, a potent vasodilator that causes the
symptoms of swelling and pain characteristic of an HAE
attack.4-6
Ecallantide (KALBITOR; Dyax Corp, Burlington, Mass) is a
recombinant protein inhibitor of human plasma kallikrein pro-
duced in the yeast Pichia pastoris.7,8 It is indicated for the
treatment of acute attacks of HAE of patients 12 years of age and
older.9 The safety and efﬁcacy of ecallantide were demonstratedin 2 randomized, double-blinded, placebo-controlled phase 3
studies, Evaluation of DX-88s Effects in Mitigating Angioedema
(EDEMA) 3 Double Blind (EDEMA3-Double Blind) and
EDEMA4 (Dyax Corp, Burlington, Mass).10-12 In both
studies, clinical efﬁcacy was evaluated by using 2 validated, HAE-
speciﬁc, patient-reported outcomes: the Treatment Outcome
Score and the Mean Symptom Complex Severity score.13 The
Treatment Outcome Score is a measurement of symptom
response to treatment, and the Mean Symptom Complex
Severity score is a point-in-time measurement of symptom
severity. When using both measurements, 30 mg of SC ecal-
lantide was superior to placebo in relieving symptoms and in
decreasing the severity of attacks.10,11 Symptom relief was du-
rable, with sustained symptom relief observed up to 24 hours
after ecallantide treatment.10,11
The use of ecallantide is associated with anaphylaxis in 3% to
4% of treated patients.9 The drug, therefore, should only be
administered by a health care professional with appropriate
medical support to manage anaphylaxis and HAE.9 In this
analysis, we conducted a retrospective review of cases of
anaphylaxis reported during the clinical development program
for ecallantide to ascertain if these cases represent type I hyper-
sensitivity reactions. The analysis included all the patients treated
with either SC or intravenous (IV) ecallantide during clinical
trials: EDEMA0, EDEMA1, EDEMA2, EDEMA3 (Double-
Blind and Repeat-Dosing arms), EDEMA4, and DX-88/19.
Only the SC formulation of ecallantide is currently approved and
available for clinical use in the United States.
METHODS
This analysis included all cases of potential hypersensitivity
reactions identiﬁed in the ecallantide HAE clinical development
program (EDEMA0, EDEMA1, EDEMA2, EDEMA3 [Double-
Blind and Repeat-Dosing], EDEMA4, and DX-88/19). Ecal-
lantide was administered by IV in EDEMA0 and EDEMA1;
either IV or SC in EDEMA2; and only SC in EDEMA3 (Double
Blind and Repeat-Dosing arms), EDEMA4, and DX-88/19. A
change in the ecallantide manufacturing process occurred during
EDEMA2 in which an additional puriﬁcation step was added.
This step decreased the amount of residual P pastoris host cell
protein in the drug product. All SC doses of the drug were
produced with this additional puriﬁcation step. IV doses of
ecallantide administered in EDEMA0, EDEMA1, and portions
of EDEMA2 did not include the additional puriﬁcation step,
and, therefore, the residual amounts of P pastoris differed be-
tween the SC and IV doses. All the studies were institutional
review board-approved, and all the patients provided written
informed consent. For inclusion in the clinical studies, patients
had to be 10 years old, except in EDEMA0, in which the
subjects were 18 years of age, with moderate-to-severe acute
HAE attacks (DX-88/19 also included mild attacks).
Identification and adjudication of hypersensitivity
reactions
The database listing of treatment emergent adverse events,
deﬁned as those events with onset during or after ecallantide
dosing, was searched for cases that had adverse event terms that
may be associated with type I hypersensitivity reactions. These
terms included “adverse drug reaction,” “anaphylaxis,” “anaphy-
lactic reaction,” “anaphylactoid reaction,” “hypersensitivity,” “er-
ythema,” “ﬂushing,” “hot ﬂush,” “pharyngeal edema,” “laryngeal
TABLE I. Clinical criteria for diagnosing anaphylaxis
Anaphylaxis is highly likely when any one of the following 3 criteria are
fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of
the skin, mucosal tissue, or both (eg, generalized hives; pruritus or
ﬂushing; swollen lips, tongue, uvula), and at least 1 of the following:
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm,
stridor, reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction (eg,
hypotonia [collapse], syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a
likely allergy for that patient (minutes to several hours):
a. Involvement of the skin-mucosal tissue (eg, generalized hives; itch-
ﬂush; swollen lips, tongue, uvula)
b. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm,
stridor, reduced PEF, hypoxemia)
c. Reduced BP or associated symptoms of end-organ dysfunction (eg,
hypotonia [collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain,
vomiting)
3. Reduced BP after exposure to known allergen for that patient (minutes
to several hours):
a. Infants and children: low systolic BP (age speciﬁc) or more than 30%
decrease in systolic BP*
b. Adults: systolic BP of lower than 90 mm Hg or more than 30%
decrease form that person’s baseline
BP, Blood pressure; PEF, peak expiratory ﬂow.
Reprinted from the Journal of Allergy and Clinical Immunology, Volume 117,
Sampson et al, Second symposium on the deﬁnition and management of anaphy-
laxis: summary report—Second National Institute of Allergy and Infectious Disease/
Food Allergy and Anaphylaxis Network Symposium, pages 391-397, 2006, with
permission from Elsevier.14
*Low systolic bp for children is deﬁned as <70 mm Hg from 1 mo to 1 y, lower than
(70 mm Hg þ [2  age]) from 1 to 10 y, and <90 mm Hg from 11 to 17 y.
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erythematous,” “rhinitis allergic,” “rhinorrhea,” “throat irritation,”
“urticaria,” “urticaria localized,” “dyspnea,” and “wheezing.”
“Angioedema” was not included in the list of terms. The National
Institute of Allergy and InfectiousDisease (NIAID) clinical criteria
for diagnosing anaphylaxis, which was used to determine
anaphylaxis in this study, are shown in Table I.14 Records of cases
for any treatment emergent adverse events with these terms then
underwent a manual medical review to identify potential hyper-
sensitivity reactions, with considering factors such as timing of
treatment emergent adverse events in relationship to dose (ie,
occurred within 24 hours of study drug administration), accom-
panying symptoms, causality assessment of the investigator (typi-
cally reported as possibly, probably, or deﬁnitely related to study
drug), and any other available clinical information.
Rechallenge: skin test and test dose procedures
Patients who experienced a hypersensitivity reaction in
EDEMA1, EDEMA2, or EDEMA3 were eligible to undergo
rechallenge procedures to further deﬁne their sensitivity to
ecallantide. The rechallenge testing procedure was separated into
2 phases: a skin-testing phase and a test-dosing phase. The pa-
tients proceeded through each phase, depending on their reaction
to ecallantide after each dose and the investigator’s discretion.
After signing the separate informed consent, the patients entered
the skin-testing phase of the rechallenge. Escalating amounts of
ecallantide, along with positive and negative controls (histamine
and saline solution, respectively), were administered by a series of
skin pricks and intradermal injections. If skin testing was nega-
tive, then the patients could enter the test-dosing phase. The
patients in the test-dosing phase received escalating doses of
ecallantide through a series of 4 distinct IV infusions, of 3, 4.5,
7.5, and 15 mg of ecallantide, each separated by 30 minutes. The
patients did not undergo any desensitization before rechallenge
testing. If a patient experienced a positive reaction to ecallantide
at any time during the rechallenge, and the investigator assessed
the symptoms as indicative of a hypersensitivity reaction, then
the rechallenge procedure was stopped.
Antibody testing
The assays used to measure antibody responses to ecallantide
evolved during clinical development. Immunogenicity of ecal-
lantide was initially measured by using an indirect ELISA for
detection of non-IgE (IgM, IgG, or IgA) to ecallantide and IgE
to ecallantide or P pastoris. These assays were used in the
EDEMA0, EDEMA1, and EDEMA2 studies. During the clin-
ical development of ecallantide, Dyax developed and validated
new antibody assays in line with industry consensus recom-
mendations and International Conference on Harmonisation
guidelines(http://www.ich.org/products/guidelines.html). The
new assays consisted of an electrochemiluminescent (ECL)
ligand-binding assay designed to detect all classes of antibodies
(IgM, IgG, IgA, and IgE) to ecallantide in human serum by
using the Meso Scale Discovery detection system (Meso Scale
Discovery, Rockville, Md) and direct ELISAs for detection of IgE
to ecallantide or P pastoris proteins.
These new assays were used in the EDEMA3, EDEMA4, and
DX-88/19 studies to screen, conﬁrm, and titer all classes of anti-
ecallantide antibodies (IgM, IgG, IgA, and IgE). The new assays
represented signiﬁcant improvements in assay format. The ECL
assay in particular has a greater dynamic range and less potential fordrug interference.Detailedmethodology of these assays is provided
in the SupplementaryMethods (in this article’s Online Repository
at www.jaci-inpractice.org). The performance characteristics of
each of the assays used in the clinical development program for
ecallantide are provided in Table E1 (in this article’s Online Re-
pository at www.jaci-inpractice.org). To be conservative, patients
were considered positive if they had a positive result in the initial
screening but the titer and/or conﬁrmatory result were missing.
Patients who had 1 positive serum sample test were considered to
be positive for the rest of the clinical development program,
regardless of the presence of any subsequent negative test results.RESULTS
Hypersensitivity reactions after ecallantide
administration that met the definition of
anaphylaxis based on NIAID criteria
During the ecallantide clinical development program, 297
unique patients with HAE were treated with 1302 doses of ecal-
lantide (including IV and SC doses). Of the 297 unique patients,
230 patients received 1045 doses of SC ecallantide. The mean
patient age was 34.6 years (range, 10-78 years); 65.7% of patients
were female patients, and 85.4% were white. Potential hypersen-
sitivity reaction cases from 32 patients (20 SC, 12 IV) were iden-
tiﬁed for further analysis. Among these patients, 13 (8 SC, 5 IV)
had reactions that met the NIAID criteria for anaphylaxis, and 19
FIGURE 1. Overview of hypersensitivity reactions after ecallan-
tide administration reported in the clinical development program.
*Patients had reactions after IV and SC treatment for separate
attacks. HSR, Hypersensitivity reaction.
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NIAID criteria for anaphylaxis (Figure 1; see Table E2 in this ar-
ticle’s Online Repository at www.jaci-inpractice.org for details of
reactions that did not meet NIAID criteria). To better understand
the cases of anaphylaxis, these NIAID-positive cases were charac-
terized in further detail (Table II).
After SC administration, there were no cases of anaphylaxis
that occurred on the ﬁrst exposure to the drug. All 8 NIAID-
positive reactions after SC administration had an onset of
symptoms within 1 hour of drug exposure, and all were associ-
ated with cutaneous symptoms, such as urticaria, pruritus, ery-
thema, or ﬂushing. None of the reactions required measures
beyond standard management of type I hypersensitivity (eg,
epinephrine, antihistamines, corticosteroids, IV ﬂuids, supple-
mental oxygen), and all resolved without fatal outcomes. One
patient (Table II, patient no. 3) was transported to the emer-
gency department and held for overnight observation after SC
ecallantide administration in episode 5. This patient was dis-
charged the following morning, and all symptoms resolved
without further sequelae.
After IV dosing of ecallantide, 5 reactions met the NIAID
criteria for anaphylaxis (Table II). In contrast to cases of
anaphylaxis after SC dosing, all of these reactions occurred on the
ﬁrst exposure. Three of the IV reactions had a symptom onset
within 60 minutes of exposure, and 2 reactions had an unknown
time of onset. Two of the 5 patients with IV reactions presented
with cutaneous manifestations suggestive of type I hypersensi-
tivity, including urticaria and/or pruritus. Four of the IV re-
actions were associated with nasal symptoms suggestive of
histamine release, such as sneezing, rhinorrhea, and throat itch-
ing; urticaria; or other systemic symptoms. All of these reactions
resolved with epinephrine, corticosteroids, antihistamines and/or
bronchodilators, or without speciﬁc therapy for the reaction.
There were no fatal outcomes, and no reactions after IV
administration required hospitalization. A summary of the clin-
ical characteristics of the hypersensitivity reactions that met the
NIAID criteria for anaphylaxis after both SC and IV dosing is
provided in Table III.Rechallenge outcomes
Of the 8 patients with reactions that met the NIAID criteria
for anaphylaxis after SC ecallantide, 5 patients had additional
exposure to ecallantide (Table II; patient nos. 1, 5, 6, 7, and 8).
This re-exposure occurred either as part of the rechallenge pro-
cedure or during additional treatment episodes. The outcomes of
these reexposures were as follows: patient no. 1 had a hyper-
sensitivity reaction on rechallenge. The reaction included a
positive skin test and anaphylactic reaction to an IV partial dose
of ecallantide after pretreatment with hydroxyzine and predni-
sone. This patient did not receive any additional doses of ecal-
lantide. Patient no. 5 developed a 4-mm wheal after an undiluted
dose of ecallantide (0.2 mg) during a skin prickepuncture test
and did not receive any additional doses of ecallantide after this
reaction. With the remaining 3 cases (Table II; patient nos. 6, 7,
and 8), the patients did not have recurrence of hypersensitivity
on reexposure to ecallantide. Patient no. 6 underwent a skin test
and test-dose procedure, with no evidence of hypersensitivity and
went on to receive >20 additional doses of ecallantide; patient
nos. 7 and 8 did not undergo rechallenge procedures but received
ecallantide treatment for 1 additional episode, and no hyper-
sensitivity reactions were reported.
Three of the 5 patients (Table II; patient nos. 10, 11, and 13)
with hypersensitivity reactions that met the NIAID criteria for
anaphylaxis after IV ecallantide underwent the skin-testing and
test-dose procedure. Two of these patients had a negative skin
test but displayed symptoms of hypersensitivity during the test-
dose procedure. The third patient had a negative skin test and
test dose but did not receive any additional doses of ecallantide.
Antibody status
As a general screen to detect the presence of antidrug anti-
bodies (any class), antibody testing to ecallantide was con-
ducted with all the patients in the clinical development
program for ecallantide. In the overall population (both IV and
SC), a total of 60 of 297 patients (20.2%) were positive for
anti-ecallantide antibodies (IgG, IgA, IgM, or IgE), but the
clear majority of these patients did not have hypersensitivity
reactions. All 8 patients with anaphylaxis after SC adminis-
tration tested positive for anti-ecallantide antibodies (any
class). There was a lack of consistent positivity for IgE anti-
bodies to ecallantide or P pastoris among these 8 patients with
anaphylaxis. Three patients had positive test results for anti-
ecallantide IgE but not for antieP pastoris IgE, 1 patient had
positive test results for antieP pastoris IgE but not for anti-
ecallantide IgE, 2 patients had positive test results for both
anti-ecallantide IgE and antieP pastoris IgE, and 2 patients had
negative test results for both ecallantide IgE and P pastoris IgE
(Table II). Furthermore, antibody status was not reliably
predictive of future hypersensitivity reactions with these pa-
tients. Patient nos. 6 and 7 tested positive for anti-ecallantide
IgE but displayed no symptoms of hypersensitivity after sub-
sequent doses of ecallantide. Patient no. 8 tested positive for
both anti-ecallantide IgE and antieP pastoris IgE before
treatment in episode 13 but did not have a hypersensitivity
reaction after a subsequent dose in episode 14. In addition,
none of the patients with reactions that met the NIAID criteria
for anaphylaxis after IV administration tested positive for IgE
antibodies to ecallantide or P pastoris (Table II). Unrelated to
hypersensitivity, but important to the discussion of antibody
testing, is the observation that anti-ecallantide antibody
TABLE II. Patients with hypersensitivity reactions during ecallantide clinical studies that met the definition of anaphylaxis based on NIAID criteria*
Patient
no.
Treatment
episode†
Dose
(mg)
and
route Hypersensitivity symptoms
Time to
onset
(min) Treatment
Skin test and/or
rechallenge
Subsequent
doses and
outcome
Anti-ecal
IgE
AntieP
pastoris
IgE
1 19 30 SC Erythema, pruritus, bp
82/56 mm Hg, O2 sat 90%
12 Antihistamine (diphenhydramine 50 mg PO),
epinephrine 0.3 mL IM, supplemental
O2, lorazepam 0.5 mg PO
Skin test (D) None L D
2 6 30 SC Pruritus, erythema, urticaria,
lightheaded with thready
radial pulse, tachycardia,
extremities cool to the touch
5-25 Antihistamine (diphenhydramine 50
mg PO), epinephrine 0.3 mL IM
Not done None D L
3 5 30 SC Pruritus, erythema, dizziness,
nausea, confusion,
vomiting, tachycardia
1 Antihistamines (hydroxyzine 50 mg IM,
famotidine 20 mg IV), epinephrine 0.3
mg IM, methylprednisolone 125 mg IV,
saline solution 1 L IV, hydromorphone
1 mg IV, ondansetron 8 mg IV
Not done None D D
4 15 30 SC Flushing, chest discomfort 31 Antihistamine (diphenhydramine 25 mg
IV), albuterol 3 mL IV,
methylprednisolone 100 mg IV
Not done None L L
5 12 30 SC Flushing, chills 5-20 None Not done  
14 30 SC Flushing 6 None Not done  
15 30 SC Hot ﬂush, ﬂushing, dyspnea 4 None Skin test (D) None L L
6 6 30 SC Pruritus, erythema, dizziness,
nausea, diaphoresis,
ﬂushing, feeling faint
10 Antihistamines (diphenhydramine 50 mg
PO, cetirizine 10 mg PO, ranitidine 150
mg PO), epinephrine 0.3 mL IM,
hydrocortisone 100 mg IV
Skin test (L),
rechallenge (L)
>20, no
HSR
D L
7 7 30 SC Dyspnea, laryngeal edema,
injection site erythema, rash
41 None Not done 1, no HSR D L
8 8 30 SC Flushing, hot ﬂush 16 Antihistamine (chlorpheniramine 4 mg
PO), hydrocortisone 200 mg IV,
prednisolone 15 mg PO
Not done  þ
10 30 SC Hot ﬂush 18 None Not done  þ
13 30 SC Hot ﬂush, dyspnea, pruritus,
dizziness
5 D5W 1 L IV, salbutamol 5 mg
inhalation, supplemental O2
Not done 1, no HSR D D
9 1 40 IV Dysphagia, pruritus, urticaria,
edema, dyspnea, abdominal
pain, enteritis
5 Antihistamine (dexchlorpheniramine
maleate 5 mg IV), epinephrine 0.3
mL SC, hydrocortisone 100 mg IV
Not done None L L
10 1 47.8 IV Acute allergic rhinitis with
throat edema, sneezing,
itchy throat, congestion,
nasal drainage, shortness
of breath
Unknown Antihistamines (diphenhydramine 50 mg
PO, cetirizine 3 mg PO), epinephrine
(0.3 mg IM); prednisone 40 mg PO
Skin test (L);
test dose:
rhinorrhea
None L L
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CRAIG ETAL 211positivity did not appear to reduce the clinical efﬁcacy of
ecallantide in treating HAE attacks.DISCUSSION
The clinical development program of ecallantide included
studies in which ecallantide was administered IV (EDEMA0,
EDEMA1, and EDEMA2) and SC (EDEMA2, EDEMA3-
Double-Blind, EDEMA3eRepeat-Dosing, EDEMA4, and
DX88/19), and hypersensitivity reactions occurred after either
route of administration. Symptoms included pruritus, urticaria,
erythema, ﬂushing, dyspnea, chest discomfort, dizziness, nausea,
hypotension, and laryngeal edema. In total, there were 13 of 297
patients (4.4%) treated either with IV or SC ecallantide, who had
potential hypersensitivity reactions that met the NIAID criteria
for anaphylaxis; 8 of 230 patients (3.5%) treated with the
approved SC formulation had potential hypersensitivity reactions
that met the NIAID criteria. The rates reported here are
consistent with what is included in the current product labeling
for ecallantide (3% to 4%).9
After SC administration, no cases of anaphylaxis occurred on
ﬁrst exposure to the drug. The timing of symptom onset was
suggestive of a type I hypersensitivity reaction because symptoms
in all cases after SC administration began within 1 hour of drug
exposure. In addition, all of the cases were associated with cuta-
neous manifestations also suggestive of an IgE-mediated hyper-
sensitivity reaction, such as urticaria, pruritus, erythema, or
ﬂushing. However, a small subset of these patients did not have
recurrence of their reaction upon subsequent reexposure, which
argues against a type I hypersensitivity etiology in those cases. The
reactions, except one, did not require any treatments beyond those
typically used in managing type I hypersensitivity reactions, and,
although there was 1 hospitalization, there were no fatal outcomes.
The pattern of hypersensitivity reactions after IV administration
was different from that after SC administration, which suggests that
IV reactions may be mediated by a different mechanism, such as
non-IgEemediated mast cell activation. Notably, all reactions that
met the NIAID criteria for anaphylaxis after IV administration
occurred on ﬁrst exposure to the drug, which suggests that patients
may already have been presensitized to the drug product, such as a
component related to P pastoris, the cells used to manufacture
ecallantide. However, none of the patients with anaphylaxis after IV
infusion tested positive for antieP pastoris IgE. The change in the
puriﬁcation process of ecallantide that occurred during EDEMA2
also may be part of the explanation. All SC doses of ecallantide
included an additional puriﬁcation step, which reduced residual P
pastoris, and this could potentially explain the difference in the
observed pattern of hypersensitivity reactions after SC and IV
ecallantide. However, there are not sufﬁcient data to support any
particular mechanism to explain the pattern of reactions.
As summarized in Table II, not all cases of hypersensitivity (6
of 13) that met the NIAID criteria for anaphylaxis were treated
with epinephrine, the treatment of choice for anaphylaxis. A
possible explanation for this ﬁnding is that, early in clinical
development, a causal link between ecallantide administration
and hypersensitivity was not clear and the extent of anaphylaxis
risk was not understood. At the time of some of the events,
investigators may not have necessarily viewed the constellation of
symptoms as representing anaphylaxis. Only as the clinical
development program progressed did the extent of anaphylaxis
risk become apparent, which led to the boxed warning for
TABLE III. Clinical characteristics of hypersensitivity reactions
that met NIAID criteria for anaphylaxis after ecallantide exposure
SC, no. (%)
(n [ 8)
IV, no. (%)
(n [ 5)
Reaction occurred on ﬁrst exposure 0 (0) 5 (100)
Time of onset <1 h 8 (100) 3 (100)*
Cutaneous manifestations suggestive
of type I hypersensitivity†
8 (100) 2 (40)z
Reactions failing to respond to
conventional type I hypersensitivity
management
0 (0) 0 (0)
*Times of onset of 2 reactions were unknown.
†Cutaneous manifestations ¼ pruritus, urticaria, ﬂushing, hot ﬂush, rash.
zAlthough only 40% of the patients of the IV anaphylaxis cases presented with
cutaneous manifestations suggestive of type I HSR, 4 of 5 of the patients (80%) of
the IV cases presented with upper respiratory tract manifestations suggestive of mast
cell degranulation; these symptoms included sneezing, rhinorrhea, allergic rhinitis,
and/or throat itching.
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by a health care professional with appropriate medical support to
manage anaphylaxis and HAE.
Results from antidrug IgE antibody testing did not conﬁrm
the mechanism of the hypersensitivity reactions. There was a lack
of consistent positivity to IgE antibodies to ecallantide or
P pastoris, and none of the IV anaphylaxis cases had a positive
antidrug IgE result. In addition, some patients tested positive for
antidrug IgE but did not develop symptoms of hypersensitivity
after subsequent drug exposure. It should be noted that detection
of circulating antidrug IgE antibodies can be challenging due to
the association of IgE on the surface of mast cells and resulting
low concentration of IgE in the circulation. Skin testing is a
common diagnostic procedure for evaluating potential drug hy-
persensitivity.15,16 In the cases reviewed here, many patients with
reported hypersensitivity reactions did not undergo skin testing.
Due to this major limitation in the data, the predictive value of
skin testing remains unknown.
Due to the lack of skin testing data and the insufﬁcient pre-
dictive value of in vitro antidrug IgE antibody testing, a reliable
diagnostic test for assessing hypersensitivity remains unavailable,
and the possible mechanism of the reactions remains unknown.
Nonetheless, a review of the clinical presentations in these
anaphylaxis episodes providedmeaningful information.Due to the
overlap of symptoms in anaphylaxis and HAE attacks, dis-
tinguishing between the 2 events after ecallantide administration is
an important consideration for health care professionals. As
observed in these cases, rapid onset of symptoms after dosing, the
presence of cutaneous manifestations commonly associated with
mast cell degranulation (eg, urticaria), and response to standard
type I hypersensitivity reaction treatment were consistently
observed in anaphylaxis episodes after SC ecallantide administra-
tion. It should be noted that the same clinical presentation may be
observed after complement-mediated mast cell activation but thedata available from the clinical development program for ecallan-
tide do not allow deﬁnitive mechanistic conclusions to be made.CONCLUSION
Ecallantide use is associated with a low but important risk of
anaphylaxis. The underlying mechanism for these anaphylaxis
episodes is unclear, and no predictive risk factor could be iden-
tiﬁed. The clinical features described herein may serve as helpful
indicators to guide clinicians in evaluating cases of potential
hypersensitivity reactions after ecallantide administration.
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Antibody Assays
The assays used to measure antibody responses to ecallantide
evolved during clinical development. Immunogenicity (non-IgE)
of ecallantide was initially measured by using an ELISA format.
This method was replaced with a bridging ECL format that had
increased sensitivity and dynamic range, and less potential for
drug interference. Assays to detect antibodies to P pastoris host
cell proteins were initially developed with surrogate controls that
required multiple assay formats on the same plate. These
methods were reﬁned with the introduction of a unique
bifunctional control that allowed for a single direct binding
format. The ECL anti-ecallantide antibody assay and ELISA for
ecallantide IgE and P pastoris IgE were used in both pivotal phase
3 clinical studies EDEMA3 and EDEMA4. Details of the assay
methods are provided in Supplementary Methods sections Assay
1 and Assay 2.
Non-IgE anti-ecallantide antibodies ELISA assays
ELISA methods were developed for the detection of anti-
ecallantide antibodies. These assays were termed non-IgE anti-
ecallantide responses because the secondary or detection antibody
could possibly detect IgA and IgM antibodies in addition to IgG
antibodies.
Assay 1. Plates were coated with ecallantide standard, and
assay reference standards, controls, and human serum were added
and incubated. After incubation, anti-ecallantide antibodies
bound to the plate were detected by using a secondary donkey
antihuman IgG-heavy and light chain antibody conjugated to
horseradish peroxidase (HRP). Because no human anti-ecallan-
tide antibodies were available, a puriﬁed rabbit polyclonal anti-
ecallantide antibody was used as the positive control that was
detected by secondary goat-antirabbit IgG Fc conjugated to
HRP. Also, 3,3’,5,5’-tetramethylbenzidine (TMB) was the
colorimetric substrate used for reading at an optical density (OD)
of 450 to 650 nm. Samples were considered positive for anti-
ecallantide antibodies when OD readings were higher than the
assay cut point, which was set at 2 times the mean OD values for
the human serum negative controls. Data were reported as OD
values.
Assay 2. Plates were coated with ecallantide standard, and assay
reference standards, controls, and human serum were added and
incubated. After incubation, anti-ecallantide antibodies bound to
the plate were detected by using a secondary goat-antihuman IgG,
IgA, IgM, heavy and light chain antibody conjugated to HRP.
Because no human anti-ecallantide antibodies were available, a
puriﬁed rabbit polyclonal anti-ecallantide antibody was used as the
positive control, which was detected by secondary goateantirabbit
IgG conjugated to HRP. TMB was the colorimetric substrate used
for reading at an OD of 450 nm. Samples were considered positive
for anti-ecallantide antibodies when OD readings were higher
than the prespeciﬁed assay cut point of 0.392 OD (20.53 U/mL).
This cut point was derived from the means  2 SDs of OD values
from 60 human serum negative controls. Data were reported as
OD U/mL. A competitive ELISA-immunodepletion assay also
was developed by using the same reagents to determine the
speciﬁcity of samples that were positive in the screening assay. In
this assay, antibody-positive serum samples spiked with ecallantide
(100 ng/mL) compete for solid phase ecallantide bound to theplate. A reduction in signal of 50% or greater indicated speciﬁcity
to ecallantide.
Non-IgE anti-ecallantide antibodies ECL assay
A Meso Scale Discovery bridging assay with ECL detection to
screen, conﬁrm, and titer all classes of anti-ecallantide antibodies
was developed. In this assay, ecallantide was conjugated with
either biotin or ruthenium, and these reagents were used for both
capture and detection. Assay reference standards, controls, and
serum samples were incubated with a mixture of both bio-
tinylated and ruthenylated ecallantide, which allowed polyclonal
anti-ecallantide antibodies to form a bridge. The mixture was
added to streptavidin-coated plates to bind the anti-ecallantide
antibody complexes. A read buffer that contained tripropylamine
was added, and an electric potential was applied to the plates.
The resulting ECL signal was proportional to the concentration
of the anti-ecallantide antibody present in the plasma sample.
Because human anti-ecallantide positive control antibodies were
not available, a puriﬁed rabbit anti-ecallantide antibody spiked
into human serum was used as the positive control.
Samples were considered positive in the screening assay when
the ECL counts were higher than the assay cut point. Plate
lotespeciﬁc cut points were established based on ECL counts
from 30 patients who were ecallantide treatment naive. To
conﬁrm the detection of anti-ecallantide-speciﬁc antibodies, the
assay was repeated in the presence and absence of 12.5 mg/mL
ecallantide. If the presence of ecallantide decreased the signal by
at least 33% or to the cut point or below, then the sample was
conﬁrmed as true positive; otherwise, the sample was considered
negative for anti-ecallantide antibodies. A third assay then was
run to establish the anti-ecallantide antibody titer. Conﬁrmed
positive samples were serially diluted, and the titer was reported
as the reciprocal of the dilution that resulted in the last positive
(above cut point) ECL response.
IgE anti-ecallantide antibody ELISA
The assay used a bifunctional reagent, which consisted of a
covalently linked puriﬁed human IgE with an afﬁnity puriﬁed
rabbiteanti-ecallantide antibody. This allowed for speciﬁc
recognition of the coated ecallantide via the rabbit antibody,
while acting as a control for the antihuman conjugate through
the IgE moiety. Plates were coated with ecallantide standard, and
assay reference standards, controls, and serum were added and
incubated. After incubation, anti-ecallantide antibodies bound to
the plate were detected by using a secondary mouse anti-human
IgE antibody conjugated to HRP. TMB was the colorimetric
substrate used for reading at an OD of 450 nm. Samples were
considered positive for anti-ecallantide antibodies when OD
readings were higher than the prespeciﬁed assay cut point. A
ﬁxed cut point was established for the assay with a value of 0.1
OD units. By using this cut point, the estimated sensitivity for
the assay would be 0.36 ng/mL.
IgE antieP pastoris antibody ELISA
This assay used a bifunctional reagent that consisted of a
covalently linked puriﬁed human IgE with an afﬁnity puriﬁed
rabbit antieP pastoris antibody, which allowed for speciﬁc
recognition of the coated P pastoris protein via the rabbit anti-
body while acting as a control for the antihuman conjugate
through the IgE moiety. Plates were coated with P pastoris
fraction A standard, and assay reference standards, controls, and
serum were added and incubated. After incubation, antieP
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secondary mouseeantihuman IgE antibody conjugated to HRP.
TMB was the colorimetric substrate used for reading at an OD of
450 nm. Samples were considered positive for antieP pastorisantibodies when OD readings were higher than the prespeciﬁed
assay cut point. A ﬁxed cut point was established for the assay
with a value of 0.08 OD units. By using this cut point, the
estimated sensitivity for the assay would be 0.52 ng/mL.
TABLE E1. Performance characteristics for assays used to measure non-IgE and IgE anti-ecal, and IgE antieP pastoris antibodies in
human serum
Study Method of analysis
Precision
LLOQ Cut pointIntra-assay (%) Interassay (%)
EDEMA0, EDEMA1 ELISA (non-IgE) (assay 1) 0.5-5.8 5.8-14.7 ND Mean OD of 2 times HSNC
EDEMA2, EDEMA3 ELISA (non-IgE) (assay 2) 6.0-18.6 9.6-26.2 0.69 U/mL 0.392 OD (20.53 U/mL)
EDEMA3, EDEMA4 ECL (non-IgE) 0-16 10-16 50 ng/mL 41.15 ECL counts
EDEMA2, EDEMA3 ELISA (IgEeanti-ecal) 3.1-13.4 6.7-32.2 0.313 ng/mL 0.192 OD (19.48 ng/mL)
EDEMA3, EDEMA4 ELISA (IgEeanti-ecal) 0-8 6-8 1.83 ng/mL (1:2 dilution) 0.06 OD units
EDEMA2, EDEMA3 ELISA (IgEeanti P pastoris) 7.7-19.7 7.1-23.5 0.156 ng/mL 0.353 OD units
EDEMA3, EDEMA4 ELISA (IgEeanti P pastoris) 0-7 5.2-7.9 3.87 ng/mL 0.06 OD units
IgE-anti-ecal, Anti-ecallantide IgE antibody; HSNC, human serum negative control; LLOQ, lower limit of quantitation; ND, not determined; OD, optical density.
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TABLE E2. Symptoms and treatment of potential hypersensitivity reactions during ecallantide clinical studies that did not meet the
definition of anaphylaxis based on NIAID criteria
Patient
no.
Treatment
episode*
Dose
(mg)
and
route
Potential hypersensitivity
symptoms
Time to
onset Treatment
Skin test
and/or
rechallenge
Reexposure
and/or
outcome
Anti-ecal
IgE
AntieP
pastoris
IgE
14 2 30 SC Urticaria 208 min Antihistamine
(diphenhydramine 50 mg
PO), ranitidine 50 mg PO
Not done None  þ
15 4 30 SC Pruritus, nausea, injection
site pruritus
12 min None Skin test (þ) None þ þ
16 1 16.9 IV Mild rash on chest Unknown None Not done  
12 30 SC Pruritus 257 min None Not done 3, no HSR  
17 9 18.7 IV Rash 1 d None Not done  þ
10 30 SC Erythema 1 d None Not done None  þ
18 2 30 SC Blood pressure increased,
ﬂushing, heart rate increased
7-10 min None Not done  
3 30 SC Chest discomfort, pain Unknown None Not done None  
19 1 30 SC Eye pruritus, nasal congestion,
sinus headache, sneezing
1 d Antihistamine (loratadine 10
mg PO); pseudophedrine
60 mg PO; acetaminophen
650 mg PO
Not done None  
20 2 30 SC Erythematous rash 75 min None Not done 7, no HSR  
21 5 30 SC Pruritus 18 h None Not done 2, no HSR  
22 2 30 SC Pruritus Unknown None Not done 1, no HSR  
23 1 30 SC Rash 118 min None Not done 11, no HSR  
24 2 30 SC Urticaria 145 min Antihistamine (loratadine
10 mg PO)
Not done None  
25 11 30 SC Pruritus, urticarial 17-19 min Antihistamine
(diphenhydramine 25 mg
IV, 25 mg PO)
Skin test ();
test dose ()
 
12 30 SC Pruritus 47 Antihistamine
(diphenhydramine 50 mg
PO); epinephrine 0.3 mL
IM; prednisone 40 mg PO
None  
26 1 36.6 IV Pruritus Unknown None Not done None  
27 3 19.7 IV Pruritus 10 min None Not done None  
28 1 87.2 IV Allergic rhinitis Unknown Antihistamine (cetirizine 1
tablet PO); oxymetazoline
4 sprays nasal
Skin test ();
test dose ()
None  
29 3 17.9 IV Generalized pruritus 1 d Antihistamine
(diphenhydramine
50 mg PO)
Not done  
4 17.9 IV Localized urticaria, pruritic rash 1 d Antihistamine
(diphenhydramine
50 mg PO)
Not done 6, no HSR  
30 2 12.3 IV Cough, throat irritation Unknown None Not done  
3 12.3 IV Rhinorrhea, throat irritation Unknown Antihistamine
(desloratadine 5 mg PO)
Not done 2, no HSR  
31 5 18.6 IV Rash, macular 1 d Antihistamine
(diphenhydramine
25 mg IV)
Not done 3, no HSR  
32 6 24 IV Headache, blurred vision,
ﬂushing, urticaria, pruritus,
conjunctival redness, tearing,
increased heart rate,
increased bp
1 min Antihistamine
(diphenhydramine
25 mg PO)
Skin test (),
test dose ()
31, no HSR  
Anti-ecal IgE, Anti-ecallantide IgE antibody; antieP pastoris IgE, antieP pastoris IgE antibody; HSR, hypersensitivity reaction; PO, oral.
*Total treatment episodes across all ecallantide clinical studies of HAE; the administration of second doses of ecallantide as either dose B or for severe upper airway compromise
were not counted as a separate treatment episode.
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